Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.
Force Webinar: Gain Therapeutics 12/05 on Vimeo
Top Biotech Stocks: Gain Therapeutics & AI Stocks to Watch in 2023
Gain Therapeutics: Focused on developing new medicines for protein
Why Is Gain Therapeutics (GANX) Stock Moving Today?
Gain Therapeutics' Small Molecule Approach for CNS Diseases
Gain Therapeutics secures $10 million
Gain Therapeutics
Natália Pérez-Carmona - Director, Biology at Gain Therapeutics
Gain Therapeutics (@GainThera) / X
